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Background: Fetal mesenchymal stem/stromal cells (MSC) represent a developmentally-advantageous cell type
with translational potential.
To enhance adult MSC migration, studies have focussed on the role of the chemokine receptor CXCR4 and its ligand
SDF-1 (CXCL12), but more recent work implicates an intricate system of CXCR4 receptor dimerization, intracellular
localization, multiple ligands, splice variants and nuclear accumulation. We investigated the intracellular localization of
CXCR4 in fetal bone marrow-derived MSC and role of intracellular trafficking in CXCR4 surface expression and function.
Results: We found that up to 4% of human fetal MSC have detectable surface-localized CXCR4. In the majority of cells,
CXCR4 is located not at the cell surface, as would be required for ‘sensing’ migratory cues, but intracellularly. CXCR4
was identified in early endosomes, recycling endosomes, and lysosomes, indicating only a small percentage of CXCR4
travelling to the plasma membrane. Notably CXCR4 was also found in and around the nucleus, as detected with an
anti-CXCR4 antibody directed specifically against CXCR4 isoform 2 differing only in N-terminal sequence. After
demonstrating that endocytosis of CXCR4 is largely independent of endogenously-produced SDF-1, we next
applied the cytoskeletal inhibitors blebbistatin and dynasore to inhibit endocytotic recycling. These increased the
number of cells expressing surface CXCR4 by 10 and 5 fold respectively, and enhanced the number of cells migrating
to SDF1 in vitro (up to 2.6 fold). These molecules had a transient effect on cell morphology and adhesion, which abated
after the removal of the inhibitors, and did not alter functional stem cell properties.
Conclusions: We conclude that constitutive endocytosis is implicated in the regulation of CXCR4 membrane
expression, and suggest a novel pharmacological strategy to enhance migration of systemically-transplanted cells.
Keywords: Fetal mesenchymal stromal cells, Bone marrow, MSC, CXCR4, Chemokine receptor, Migration,
Small molecule, EndocytosisBackground
Fetal mesenchymal stem/stromal cells (fMSC) have proper-
ties intermediate between adult and embryonic stem cells,
and thus considerable therapeutic potential. Advantageous
characteristics of fetal over adult MSC include their higher
proliferative rate, greater differentiation capacity and longer
telomeres with reduced senescence [1]. Indeed, a primary
fetal bone marrow MSC line from our team had the fastest
migratory capacity of 70 cell lines assessed at a recent
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unless otherwise stated.0.000000312 kilometers per hour) [2]. Successful transla-
tion of cell therapies requires an in-depth understanding
not only of the basic stem cell properties of differentiation
and self-renewal, but also of the cell type’s adhesive and
migratory properties.
MSC can be mobilized from their sedentary niches by
a range of external stimuli and triggered to migrate to
and occupy distant tissue sites [3]. Preferential homing
to sites of tissue injury has been demonstrated with both
adult [4,5] and fetal MSC [6-8]. However poor understand-
ing of the underlying processes in adult and particularly
fetal MSC limits our ability to exploit them for targeting
MSC to regions of tissue damage. Improved homing would
facilitate therapeutic development and reduce inappropriate
uptake of MSC in healthy tissues.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the CXC family of chemokine receptors. Interaction of
CXCR4 with its ligand, stromal derived factor (SDF-1α,
CXCL12) directs the movement of cells in hematopoietic
stem cell homing [9], leukocyte trafficking [10,11] and
tumour metastasis [12,13]. The CXCR4-SDF-1α axis is
active in adult MSC, which migrate toward SDF-1α
in vitro [14]. CXCR4 is expressed on the surface of only
a subset of adult MSC, but up-regulation by viral trans-
duction increases MSC homing [15], rendering CXCR4 a
target for modulating migration. However the viral
approach is unsuitable for clinical translation due to
the risk of insertional mutagenesis. CXCR4 expression
is dynamically regulated by external cues like hypoxia
[16], and can be up-regulated in adult MSC following
in vitro priming with a mixture of cytokines, as shown
to enhance migration in vitro toward an SDF-1α gradient
as well as homing in vivo to bone marrow [17]. Recently,
SDF-1 exposure was shown to up regulate low basal
CXCR4 surface expression in fetal blood derived-MSC,
which increased chemotaxis [18].
Like other G-protein coupled receptors, CXCR4
undergoes internalization after interaction with ligand.
Ligand-induced endocytosis of CXCR4 and its internal
sequestration has been extensively studied in leukocytes
[19,20] and to a lesser degree in hematopoietic stem cells
[21,22] and tumour cells [23]. Although these studies con-
firm the existence of a general regulatory mechanism, the
extent of intracellular expression and endocytosis/recyc-
ling kinetics differs between cell types, implicating cellular
context in the regulation of CXCR4 trafficking and its
functional consequences [24,25]. The predominant intra-
cellular localization of CXCR4 suggests that dynamic
equilibrium between the cytoplasm and plasma mem-
brane may modulate CXCR4 availability at the cell surface,
and thus fMSC responsiveness to SDF-1α gradients.
We investigated the intracellular localization and traffick-
ing of CXCR4 in fetal bone marrow MSC, and treated
fMSC with blebbistatin and dynasore, specific inhibitors of
myosin IIA and dynamin subunits of the actin cytoskeleton
responsible for cytoskeletal movement and chemotaxis, and
commonly associated with G-protein endocytosis. Our
findings demonstrate that surface expression of CXCR4
on fMSC and their SDF-1α induced-chemotaxis in vitro
can be increased through inhibition of receptor endo-
cytosis. These data support further development of
small molecule agents to up-regulate the functional expres-




Fetal tissue was collected from consenting women under-
going clinically indicated termination of pregnancy inaccordance with national guidelines and as approved
by the Human Research Ethics Committee of the Royal
Brisbane and Women’s Hospital. Early trimester bone
marrow MSC (passage 1–7) derived from different donors
(n = 9, gestation 10–13 weeks) and adult bone marrow
MSC (aMSC) from a bone marrow donor were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) high glu-
cose (Invitrogen) supplemented with 10% fetal bovine
serum (FBS), 100 IU/mL penicillin, and 100 μg/mL
streptomycin (Invitrogen), expanded at 5000 cells/cm2
at 37°C with 5% CO2. Isolated fMSC and aMSC were
characterised by typical cell surface phenotype and dif-
ferentiation capacity as previously reported [26-28].
Antibodies used to characterize MSC are listed in [28].
Mesodermal differentiation methods are described in the
Additional file 1.
Priming fMSC with endocytosis inhibitors
For flow cytometry, cells were primed with (−)-blebbista-
tin (1-Phenyl-1,2,3,4-tetrahydro-4-hydroxypyrrolo [2.3-b]-
7-methylquinolin-4-one, cat. # B0560, Sigma Aldrich) and
dynasore hydrate (3-Hydroxy-naphthalene-2-carboxylic
acid (3,4-dihydroxy-benzylidene)-hydrazide hydrate, cat. #
D7693, Sigma Aldrich) as follows: cells were detached
with TrypLE Select and washed twice with serum-free
DMEM. Cells were resuspended in 600 μl of DMEM not
containing FCS but with 25 mM HEPES (4 × 104 cells/ml)
with blebbistatin or dynasore added at a concentration of
80 μM. Cells were incubated at 37°C for 15, 30 or 60 min.
For morphology and immunofluorescence studies, cells
were seeded into 24 well plates with or without glass
coverslips. When confluent, cells were washed once
with DMEM and treated as indicated. Treatment media
consisted of 250 μl of DMEM + 25 mM HEPES without
FCS and 80 μM blebbistatin or dynasore as necessary.
Vehicle treatment was 0.45% DMSO in the same media,
equivalent to the amount of DMSO in 80 μM blebbistatin
solution. Cells were imaged immediately or washed with
PBS, fixed with 1% PFA in PBS pH 7.4 for 10 min, washed
and stored in PBS at 4°C.
Flow cytometry
For flow cytometry, cells were detached using TrypLE
reagent (Invitrogen). The antibodies used are detailed in
Additional file 1: Table S1. Because of expression differ-
ences with different commercially available antibodies,
we detected intracellular and extracellular CXCR4 using
a monoclonal anti-human CXCR4 PE-Cy5 conjugated
antibody (clone 12G5) following the manufacturer’s in-
structions (1:20 dilution, eBioscience), a non-conjugated
polyclonal antibody (clone ab2074, 1:50 dilution, Abcam)
and/or a biotin-conjugated monoclonal antibody (clone
4417, 1:20 dilution, R and D Systems). For indirect stain-
ing with the polyclonal antibody, cells were incubated
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once with PBS + 2% FCS. After washing cells were resus-
pended and incubated with FITC- or Alexa 488 conjugated
secondary anti-rabbit antibody or PE- or FITC labelled
streptavidin at 4°C for 30 min. After incubation cells were
washed three times with PBS. For intracellular staining for
detection of total cellular CXCR4 (surface + cytoplasmic),
cells were fixed with 4% paraformaldehyde (Sigma) for
10 min, permeabilised with 0.5% Triton X-100 (Sigma) for
10 min, and stained with anti-human CXCR4-PE Cy5 for
30 min. Cells were analysed by FACS Calibur (Becton
Dickinson - fetal MSC, adult MSC and THP-1 cells) or
Gallios (Beckman Coulter - fetal MSC and HeLa cells).
For flow cytometry experiments the isotype controls,
analysis gates were optimized on each flow cytometer,
for permeablized or intact cells, and for each antibody,
fluorophore and cell line used according to standard
practice. For cytoplasmic staining, cells were fixed and
permeabilised as above. Cells were then stained with
CXCR4-PE-Cy5, and incubated for 5 min in 0.25 M
acetic acid (pH 4) to remove surface bound antibody.
Surface CXCR4 was expressed as a percentage of total
CXCR4 as follows: [MFI (surface CXCR4)/MFI (total
CXCR4)] × 100. The CXCR4 antibodies were validated
using THP-1 cells (leukemic monocytes, obtained from
ATCC), a control cell haematopoietic cell with consti-
tutively high surface expression. Antibodies were also
assessed in human cervical carcinoma HeLa cells
(ATCC) cultured in MSC medium.
Immunofluorescence microscopy
fMSC (P3-7) were cultured on glass coverslips and then
fixed with 4% PFA in PBS (pH 7.4) for 10 min at room
temperature [28]. Cells were washed with PBS, and then
incubated with blocking and permeabilisation buffer (2%
bovine serum albumin, 0.1% Tween) for 1 hr at room
temperature. Blocking buffer was discarded and antibodies
were diluted in diluent buffer (blocking buffer diluted 1:10
with PBS) and incubated overnight with primary antibodies
at 4°C. Rabbit anti-CXCR4 (ab2074) and either mouse
anti-Rab5, anti-Rab11A, or anti-Lamp1 (all 1:50 dilution,
detailed in Additional file 1: Table S1) was added. After
incubation with primary antibodies, cells were washed
3 × 5 min and secondary anti-mouse-Alexa 568 and
anti-rabbit Alexa 488 (1:1000 dilution, from Invitrogen)
were added. Cells were incubated with secondary anti-
bodies at room temperature for 1 hr and then washed 3 ×
5 min. Coverslips were placed on microscope slides with
Prolong Gold with DAPI mounting medium (Invitrogen).
For blebbistatin and dynasore treatment experiments,
coverslips were treated with 0.1% gelatin for 10 min prior
to seeding or seeded onto fibronectin coated chamber
slides. After inhibitor treatment, cells were fixed with pre-
warmed 1% PFA for 10 min at RT, blocked in 1% BSAwith 0.05% Tween in PBS for permeabilisation for 1 hr
prior to proceeding with antibody staining. Tween was
omitted for surface CXCR4 staining. Antibodies were di-
luted in PBS. Four x 30 sec washes were carried out after
each antibody incubation. Slides were examined on a Zeiss
Axio epi-fluorescence or LSM 510 confocal microscope.
In situ Proximity Ligation Assay (PLA)
Cells were cultured on coverslips, fixed with PFA as per
Immunofluorescence Microscopy (above). Cells were per-
meabilised with 0.1% Tween in PBS for 10 min at room
temperature. The Duolink II proximity ligation assay
(PLA, mouse-rabbit starter kit in orange, Olink Biosci-
ences) was carried out as per manufacturer’s instructions
and using supplied reagents for a 1 cm2 reaction volume.
Primary antibodies were incubated overnight at 4°C -
rabbit anti-CXCR4 (1:50, ab2074) and either mouse anti-
Rab5 (1:200, 1 μg/ml), anti-Rab11A (1:50, 1 μg/ml) or
anti-Lamp1 (1:100, 1 μg/ml) were used. The positive con-
trol was the PLA reaction between rabbit anti-Growth
Hormone Receptor (GHR) clone H300 (1:200, Santa Cruz)
and the mouse anti-GHR clone 3A12 (1:200, Sigma Al-
drich), as these 2 different antibodies detect different
epitopes of the GHR protein.
Transwell assays
Fetal MSC were detached using TrypLE reagent (Invitro-
gen), washed twice in PBS, and resuspended in DMEM.
Cells were stained for 8 min at room temperature with
CFSE (0.1 mg/ml) and the reaction was then inactivated
by adding PBS with 2% FCS. Cells were washed twice
and resuspended in DMEM with no FCS. Cells were
treated with either endocytosis inhibitors or vehicle only
(DMSO) for 1 hr. 300 μl of fMSC suspension (1.6 × 104
cells/well) were placed in the upper compartments of a
Fluoroblok transwell migration chamber (BD Biosciences).
The transwell membrane (8 μm pore size) was coated with
fibronectin 2.5 μg/ml for 30 min at room temperature,
then washed with water and allowed to air-dry. SDF-1α
was placed in the lower compartment (30, 100 or 200 ng/
ml). Cells were allowed to undergo chemotaxis for 4 hours
and then migration was determined by fluorescence inten-
sity in the bottom well using the Paradigm fluorescence
plate reader (Beckman Coulter). Each experiment was per-
formed in triplicate. The migration index was calculated
as the ratio of the fluorescence intensity of cells migrating
towards the chemo-attractant to the fluorescence intensity
of cells migrating towards media alone.
Adhesion assays
For adhesion assays, CFSE stained cells (35,000/well) were
incubated in fibronectin or collagen I coated wells of
96-well plates in DMEM containing no FBS at 37°C and
5% CO2 for 1 hr, and then washed with DMEM without
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by reading the fluorescence intensity with the Paradigm
microplate reader.
Quantitative wound healing assay
Migration was assessed by performing scratch wound as-
says in a real-time cell imaging system (IncuCyte Live-cell,
ESSEN BioScience Inc.). Briefly, 5 × 104 cells per well were
plated into an Essen-Costar 96 well plate coated with 0.1%
gelatin (n = 3 independent donors, performed in replicates
of 5). Twenty four hours later, the confluent monolayer of
cells was washed 1x PBS, scratched with the Essen Bio-
science 96 well plate scratcher, incubated with blebbistatin
or dynasore as above (80 μM, for 1 hr 37°C). The media
was removed and normal growth media added, plates
were transferred to the Incucyte live cell imaging system
and the Essen 96 well wound assay protocol was run on
the software. Cells were imaged at 4 hr intervals for 24 hr
to monitor cell migration. Wound confluence was calcu-
lated automatically by the Incucyte software (v1.5) for
12 hr, i.e. until wounds were greater than 90% confluent.
The data were then analysed using an integrated metric:
Relative Wound density.
Statistical analysis
Normally-distributed data were expressed as mean ±
standard deviation and analysed by paired t-test and
ANOVA. p < 0.05 was considered significant. All experi-
ments were conducted in triplicate or with a minimum of 3
independent donor-derived fMSC, unless otherwise stated.
For scratch wound, a 2-way ANOVA with Bonferroni cor-
rection was used (Prism, GraphPad).
Results
Fetal bone marrow derived-MSC exhibit typical MSC
characteristics
Isolated fMSC and aMSC were characterised by typical
cell surface phenotype and differentiation capacity as pre-
viously reported [26-28]. Cultured MSC met the criteria
set by the International Society for Cellular Therapy [29],
being plastic adherent, fibroblastic in morphology and
able to differentiate osteogenic, adipogenic and chondro-
genic lineages in vitro (Additional file 2: Figure S1A-D).
Fetal MSC were positive for the various MSC markers
(including CD73, CD105, CD29, CD90) and were negative
for hematopoietic and endothelial markers (including
CD45, CD11b, CD34, CD31) (Additional file 2: Figure S1E
and F).
CXCR4 expression is predominantly intracellular and
localized to the endosomal, lysosomal and nuclear
compartment of fMSC
Only 3.8 ± 0.3% of fetal bone marrow-derived mesenchymal
stem/stromal cells (fMSC, n = 4) displayed positive surfaceimmune staining for CXCR4 (Figure 1, Additional file 3:
Figure S2A). However, when cells were fixed and permeabi-
lised, ~50-90% of fMSC stained positive for intracellularly
localised CXCR4 (Figure 1B, Additional file 3: Figure S2B).
This low surface and high intracellular CXCR4 staining pat-
tern was observed regardless of the anti-CXCR4 antibody
clone used (clone 12G5, 4417 or ab2074) or the method
of antibody detection (direct or indirect fluorophore-
conjugated primary antibody). Furthermore, detaching
fMSC with enzymatic (TrypLE) or chemical methods
(5 mM EDTA) produced only a modest change in
CXCR4 (12G5) antibody surface staining (3.8% vs 5.3%,
Additional file 3: Figure S2H). Therefore, enzymatic
degradation of the CXCR4 is not a major reason for
low surface CXCR4 expression observed in this study.
A similar low surface/high intracellular CXCR4 immuno-
positivity was seen for adult bone marrow MSC (passage
5, n = 1, Figure 1C and D), as previously reported [30].
This is in contrast to THP-1 monocytic leukemic and
HeLa cell lines, that both displayed a high percentage of
cells with surface CXCR4 immuno-positivity (Figure 1E-F,
Additional file 3: Figure S2E) and previously reported mi-
gration capacity to SDF-1, the CXCR4 ligand [31,32].
Although cytoplasmic sequestration of CXCR4 has
been described in adult bone marrow and decidual MSC
[30], the internal distribution of CXCR4 has not to date
been characterised in any MSC. Two CXCR4 antibody
clones (4417 and 12G5) detected an even surface distribu-
tion of CXCR4 on a small number of fMSC by immuno-
fluorescence microscopy (Figure 2A, and not shown).
This supported the flow cytometry data that deter-
mined only 3.8 ± 0.3% fMSC had positive CXCR4 sur-
face immuno-reactivity (Figure 1). Permeabilization of
cells with Triton-X showed CXCR4 to be localized in punc-
tate endosomal/lysosomal-like compartments (Figure 2B),
some of which aligned to the cytoskeleton or nuclear mem-
brane (Figure 2B, upper and lower insets respectively).
However, the third anti-CXCR4 (ab2074) antibody tested,
produced a different pattern of diffuse punctate cytoplasmic
staining with a large accumulation of CXCR4 in the nucleus
(Figure 2D). Antibody staining conditions were optimized
as described in the additional information, but this did not
change the nuclear localization of CXCR4 detected by
the ab2074 antibody (Additional file 4: Figure S3A-C).
We thus examined the localization of CXCR4 using
well-characterised markers of the endocytotic pathway,
Rab5 and Rab11 for early/recycling endosomes, and
Lamp-1 for lysosomes. Immuno-fluorescence staining
of fMSC revealed a similar diffuse punctate distribution
of anti-CXCR4 (ab2074) antibody with both Rab5 and
Rab11 labelled endosomes (Figure 2D and E). Subcellu-
lar localization patterns of Rab5 and Rab11 were con-
firmed by transient transfection of fMSC and HeLa cells
(Additional file 4: Figure S3D and E). CXCR4 staining
Figure 1 A low number of human fetal bone marrow MSC (fMSC) display surface CXCR4. Three different anti-CXCR4 antibody clones were
used 12G5, ab2074 and 4417 as detailed in the methods, with fluorophore labelled secondary antibodies used where necessary. A) CXCR4 surface
expression (fluorescence intensity vs. forward scatter) by flow cytometry shown as dot plots. B) After permeabilisation, the majority of cells show
intracellular stores of CXCR4. The horizontal gates delineate the position of relevant isotype control antibody. Human adult bone marrow MSC
also show low expression of CXCR4 on the cell surface (C) with large intracellular stores of this receptor (D). E) Each of the anti-CXCR4 antibodies
are able to detect >80% cells with surface expression of CXCR4 on HeLa cells. F) Both the anti-CXCR4 antibodies 12G5 and ab2074 are able to
detect >80% cells with surface expression of CXCR4 on THP-1 human monocytic leukemia cells.
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Lamp1, although Lamp1 displayed a different peri-nuclear
location (Figure 2F).To confirm co-localization of CXCR4 in endosomal
compartments, an in cell co-immunoprecipation (prox-
imity ligation assay, PLA) was conducted (Figure 2G).
Figure 2 Subcellular localization of CXCR4 expression in MSC. A) Incubation of non-permeabilised fMSC with the anti-CXCR4 antibody (clone
4417) shows a distinct plasma membrane labelling of a small percentage of cells (a representative image of positive cell in the centre is shown).
B) When incubated with permeabilised fMSC, the anti-CXCR4 (4417) antibody labels endosomal-like structures in a majority of cells. These CXCR4
positive vesicles have an arrangement along the cytoskeleton (upper inset) and also perinuclear accumulation (lower inset) with light nuclear
staining. C) Negative control for ab 4417, using the same imaging settings. D-F) Immunofluorescence staining of fMSC with anti-CXCR4 clone
ab2074 (red) strong nuclear localization of CXCR4, with diffuse, punctate cytoplasmic staining. CXCR4 colocalises with the endocytotic markers
Rab5 (D) and Rab11 (E) and lysosomal marker Lamp1 (F, all green). Lamp1 displays a distinct peri-nuclear location, with larger sized vesicles.
Nuclei, counterstained with DAPI (x40 magnification). G) The Duolink II proximity ligation assay (PLA) shows colocalisation of CXCR4 (ab2074)
with all three Rab5, Rab11 and Lamp1 positive compartments. Each red spot corresponds to a molecular interaction (x20 magnification). H) The
positive control experiment is two different antibodies to the Growth Hormone Receptor, where the bound antibodies are in close proximity to
each other. Negative controls have one (#1) or both (#2) primary antibodies omitted from the PLA procedure.
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Rab11 and Lamp1, with each red spot indicating a point
of co-localization. Positive and negative controls for the
PLA assay shown in Figure 2H support the specificity ofthese CXCR4 interactions. These PLA results are con-
sistent with the immunofluorescence microscopy, and
indicate that cytoplasmic CXCR4 in fMSC is distributed
within all three endosomal compartments.
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we investigated whether endogenously-produced SDF-1α,
the CXCR4 ligand highly expressed in MSC [33], could
trigger this endocytosis of CXCR4 through a ligand-
dependent process. Fetal MSC expressed very low levels
of CXCR4 mRNA, consistent with recycling of receptors
rather than synthesis (Additional file 5: Figure S4A). Al-
though fMSC expressed high levels of SDF-1α mRNA
(Additional file 5: Figure S4A), treatment of fMSC cultures
with a neutralizing antibody against SDF-1α produced
only a moderate increase in cell surface expression of
CXCR4, as measured by mean fluorescent intensity (MFI)
on flow cytometry (Figure 3A). This suggests although
ligand-dependent endocytosis occurs, it cannot account
for all and particularly basal receptor internalization, and
thus an overriding constitutive mechanism is likely to be
responsible for the CXCR4 trafficking pattern observed.
Treatment with endocytosis inhibitors increases CXCR4
surface expression
Given the large proportion of CXCR4 located within the
endosomal compartment, we explored the regulatory
mechanism responsible by using two inhibitors of endo-
cytosis, blebbistatin and dynasore, to probe the dynamics
of CXCR4 trafficking. Blebbistatin is an inhibitor of non-
muscle myosin II and inhibits endocytosis, while dynasore
is a small molecule inhibitor of dynamin I and dynamin II
proteins with important roles in clathrin-dependent endo-
cytosis. fMSC were initially treated with different concen-
trations (ranging from 20–100 μM) of either blebbistatin
or dynasore. After 30 min the highest levels of surface
CXCR4 expression determined by flow cytometry (bleb-
bistatin: 22.6% ± 7.9 of cells; dynasore: 17.2% ± 3.8 of cells,
n = 3) were achieved at a concentration of 80 μM for both
agents (p < 0.01, Figure 3D). Quantitatively similar results
were obtained using a different anti-CXCR4 antibody
(ab2074) and an indirect staining method on adult
MSC (blebbistatin: 20.5% ± 3.0 of cells and dynasore:
16.4% ± 2.4 of cells, Figure 3E). To determine the kinetics
of CXCR4 receptor exocytosis, fMSC were treated with
80 μM blebbistatin or dynasore (n = 3 each) at 37°C and
the cells then collected at select time points. The cells
were stained with CXCR4 antibody (12G5), fixed and the
level of surface and cytoplasmic CXCR4 expression exam-
ined by flow cytometry. Blebbistatin resulted in a return of
CXCR4 to the cell surface with maximal surface expres-
sion (33.4% ± 11.3 of cells) reaching steady state after
1 hour (Figure 3C). Dynasore treatment revealed a similar
return of surface expression of CXCR4, but with a lower
maximal level (25.6% ± 5.4 of cells) compared with bleb-
bistatin. After two hours, CXCR4 surface expression
was maintained stably at a level around 5 fold higher
than untreated control MSC, but returned to baseline over
the subsequent 6 hours (not shown). These endocytosisinhibitors also reduced ligand-induced internalization of
CXCR4 in THP-1 cells. This hematopoietic leukemic cell
line served as a control cell type with >90% endogenous
surface expression when untreated, whereas SDF-1 treat-
ment induced rapid internalization of CXCR4 (Figure 3F
and G). However, co-incubation of THP-1 cells with SDF-
1 and blebbistatin or dynasore kept the surface levels of
CXCR4 similar to untreated (Figure 3H and I).
Translocation kinetics and modelling indicates CXCR4
endocytosis rate regulates surface expression of CXCR4
At steady state, the relative distribution of a membrane
protein between the surface and interior of cells is deter-
mined by the ratio of the recycling to endocytosis rate con-
stants. Inhibition of endocytosis in fMSC with blebbistatin
and dynasore permits an approximation of a recycling rate
(kr) and thus derivation of the endocytosis rate (ke). The
high rate of basal endocytosis is consistent with high
cytoplasmic sequestration of CXCR4 and the low surface
expression we document in fMSC.
Additional file 6: Figure S5B shows the fit of the above
model to the experimental data obtained before and after
treatment with blebbistatin or dynasore. Simulations using
rate constants derived from the experimental data show
levels of CXCR4 surface expression of 4.8% for resting
fMSC, 35% for blebbistatin and 26% for dynasore.
Additional file 6: Figure S5C shows a simulation in which
the total cellular CXCR4 is initially present in the intracel-
lular pool. As the system approaches equilibrium, CXCR4
is transferred from the cytoplasmic compartment to the
cell surface. Simulations show that the level of membrane
expression of CXCR4 in fMSC is sensitive to the rate of
endocytosis (ke). The series of theoretical curves generated
demonstrate how ke and kr inter-determine the level of
CXCR4 receptor surface expression and internalization in
fMSC. Additional file 6: Figure S5C shows the effect on
receptor cell surface expression level of varying ke while
maintaining kr at its basal rate (0.04 min
−1). When ke is
small, little internalization is seen and a large proportion
of CXCR4 in present on the cell surface (~70%), but as ke
rises, a greater proportion of receptors are found inside
the cell at steady state. Thus, fMSC that exhibit small kr
and large ke have substantial levels of internalization. The
model also demonstrates that altering the rate of endo-
cytosis independent of the recycling rate is sufficient to
cause substantial receptor re-surfacing. The model sup-
ports the rate of endocytosis of CXCR4 being a critical
regulatory point for surface expression of CXCR4 in
fMSC, and one amenable to manipulation.
Transient effect of endocytosis inhibitors on fMSC
morphology and cytoskeleton arrangement
The treatment of blebbistatin and dynasore had a marked
effect on the morphology and fragility of cells (Figure 4
Figure 3 Surface CXCR4 expression increases after treatment with endocytosis inhibitors. A) Treatment of fMSC for 24 hr with a
neutralizing antibody against SDF-1 at a range of antibody concentrations. fMSC show only low level increase of CXCR4 expression (MFI
calculated from flow cytometry data). B) Treatment of fMSC with the endocytosis inhibitors, blebbistatin or dynasore increases surface expression
of CXCR4. Cells were treated with vehicle (0 μM) or 20–100 μM blebbistatin or dynasore for 60 min before surface expression was determined by
flow cytometry (expressed as% total cells expressing surface CXCR4 ± SD). C) Kinetics of CXCR4 exocytosis in fMSC after treatment with endocytosis
inhibitors. Cells were treated with 80 μM blebbistatin or dynasore then fixed and stained with anti-CXCR4 (12G5) at 0, 15, 30, 60, 90 and 120 min time
points. D) MSC were incubated with vehicle or 80 μM blebbistatin or dynasore for 60 min. Fetal MSC were stained with isotype control (upper panel)
or anti-CXCR4 (12G5, lower panel). (E) Inhibitor treated adult bone marrow MSC anti-CXCR4 (ab2074). Percentage of cells positive for CXCR4 expression
over isotype control is indicated. Dynasore and Blebbistatin inhibit SDF-1 induced endocytosis of CXCR4 in THP-1 cells. F) In the untreated state,
anti-CXCR4 antibody 12G5 detected >90% cells with surface expression of CXCR4 on THP-1 monocytic leukemia cells. G) Stimulation of THP-1 cells
with 1 mg/ml of SDF-1 resulted in down-regulation of surface expression of CXCR4 while co-treatment with either blebbistatin (H) or dynasore
(I) showed reduced CXCR4 endocytosis. The position of the isotype control is indicated by the gates (fluorescence intensity vs. forward scatter).
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Figure 4 Endocytosis inhibitors disrupt the actin cytoskeleton of fMSC. The morphology of the actin cytoskeleton was visualized with Alexa
568-conjugated phalloidin after incubation for 1 hr in serum-free (treatment) media, or treatment media + vehicle, blebbistatin or dynasore. A)
Cells at high confluence are less prone to cytoskeletal change, whereas cells at lower confluence are impacted more by inhibitors (B and C shows
enlargement of key regions of B). D) A schematic illustration of C, showing actin filaments as white lines, the outline of each cell as a red line,
and membrane ruffles as blue lines or spots. A normal, filamentous actin cytoskeleton is seen in fMSC with treatment media. Treatment with
vehicle (DMSO) has some impact on cytoskeletal integrity, with the partial loss of long actin filaments in most cells. Blebbistatin and dynasore
treatment dramatically disrupts the actin cytoskeleton in most cells. The cells develop membrane ruffles, neural-like projections and begin
detaching from the culture dish (x40 magnification).
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altered the morphology of the cells’ cytoskeleton
within 15 min to a more rounded cell type with pro-
jections (Additional file 6: Figure S5), which continued
to increase over the 60 min treatment time. However,
24 hr after treatment was stopped, the cells regained
their usual shape. This was enhanced by the fact
there were no serum or attachment factors in the
media and further the vehicle, DMSO, elicited a par-
tial loss of actin cytoskeleton polymerization (Figure 4).
The change in structural features in the fMSC with differ-
ent treatments is illustrated in the schematic shown in
Figure 4D. Where a monolayer of cells was less confluent,
the inhibitor treatment had a more dramatic effect on
morphology than areas with higher cell density (Figure 4A
vs. B).
When the cellular distribution of CXCR4 and Rab5
following blebbistatin treatment was assessed by micros-
copy, there was little change in the size or distribution
of the endocytotic vesicles, or in the number of CXCR4+
endosomes (Figure 5).Partial inhibition of endocytosis does not adversely affect
directional migration and can augment CXCR4 function
We next investigated whether CXCR4 retained functional-
ity after treatment with blebbistatin and dynasore. It had
been reported that blebbistatin can disrupt cell migration
[34], although other reports suggested it may have little
adverse impact on, or even enhance, cellular migration
[35,36]. Accordingly we performed a scratch wound assay
to determine if pre-treatment of fMSC with either inhibi-
tor alters directional migration. Blebbistatin or dynasore
did not affect migration of cells into the in vitro wound
zone (Figure 6A and B, n = 3 donors).
Adhesion to extracellular matrix (ECM) proteins is im-
portant not only for tissue cohesion but also cell migration
[37]. Therefore, we assessed adhesion of treated and un-
treated fMSC to two ECM components, fibronectin and
type I collagen. Interestingly, treatment with blebbistatin
and dynasore reduced adhesion to both fibronectin and
collagen I by up to a third (p < 0.05, n = 3) compared to
untreated fMSC (Figure 6C). This suggests a role for these
inhibitors in cell mobilisation, likely via disruption of the
Figure 5 Blebbistatin does not dramatically alter the morphology of CXCR4 positive endosomes. The cellular distribution CXCR4 without
(A) and with blebbistatin treatment (B). C) Rab5 distribution with blebbistatin (80 μM, 1 hr). There was little change in the size or distribution of
the CXCR4+ or endocytotic vesicles, despite a change in actin cytoskeleton stained with phalloidin (red, A vs. B and C). However, there was a
qualitative increase in the amount of staining endosomes trapped throughout the cytoplasm in cells treated with blebbistatin (A vs. B).
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amined in a transwell assay. fMSC were either treated with
80 μM blebbistatin or 80 μM dynasore, or control-treated
with vehicle (0.45% DMSO). Cells were exposed to the in-
hibitors for 1 hour to maximize cell surface expression of
CXCR4 prior to being placed in the top chamber of
Transwell plates. Migration to three different concentra-
tions of SDF-1 (30, 100, and 200 ng/ml) was determined
after 4 hours (Figure 6D). Both blebbistatin and dynasore
enhanced chemotaxis toward SDF-1α compared to con-
trol cells, by over two fold at all concentrations examined
(2.6 fold higher than vehicle-treated cells, p < 0.01).Effect of endocytosis inhibitors on fMSC viability and
differentiation
To exclude any adverse impact of treating fMSC with in-
hibitors on cell viability and osteogenic/adipogenic differ-
entiation, fMSC were exposed to differing concentrations
of blebbistatin for 1 hour, then counted and live/dead
discrimination determined. Measures of cell survival in-
cluding Picogreen assay for DNA content and 7-AAD
flow cytometry staining showed no effect of 1 hour of
blebbistatin treatment (Additional file 7: Figure S6). Only
blebbistatin was tested as this increased the level of sur-
face CXCR4 expression the greatest.To ensure transient treatment with blebbistatin and
dynasore do not have long-term effects on mesenchymal
differentiation, fMSC exposed to either blebbistatin or
dynasore for 2 hours, and the cells then cultured under
standard inductive conditions for 3 weeks. All cultures
showed evidence of the relevant osteogenic or adipogenic
differentiation after staining with Alizarin Red or Oil Red
O (Figure 6E and F). Thus, short-term blebbistatin and
dynasore exposure had no lasting detrimental effect on
fMSC that would hinder in vivo use after inhibitor
treatment.Discussion
We report a role for CXCR4 receptor trafficking in the
migration of first trimester fetal MSC toward SDF-1.
fMSC showed a large intracellular pool of CXCR4 protein
(Figure 1), but only marginal expression of CXCR4 on the
cell surface. In this basal state, internal sequestration
of CXCR4 was associated with only modest migration
of naïve fMSC toward SDF-1. Immunofluorescence mi-
croscopy and in situ PLA experiments examining the
relationship between CXCR4 and components of the
endosomal compartment showed that CXCR4 receptors
were present within Rab5+ and Rab11+ endosomes, with
another fraction residing within Lamp1+ late endosomes/
Figure 6 Effect of endocytosis inhibitors on fMSC migration, attachment, chemotaxis and differentiation. A and B) Scratch wound assay
was carried out in a 96 well plate using the Incucyte live cell imaging system. A confluent monolayer of fMSC was wounded and treated for 1 hr
with serum-free treatment media, or treatment media with DMSO vehicle, 80 μM blebbistatin or dynasore. Images were taken 4 hourly, with
representative images of media and blebbistatin treated cells at 0, 6 and 12 hr intervals shown in A. The grey overlay is the automatically generated
wound outline at 0 hr. B) Quantitative analysis of percentage wound confluence (N = 3 donors, replicates of 5) show no statistically significant
difference in ability to migrate into the wound zone for any cell treatment. C) fMSC were prestained with CFSE, then treated with either blebbistatin or
dynasore before being placed into fibronectin or collagen I coated wells of a 96 well plate. Cell adhesion was determined by fluorescence intensity
after a 1 hr incubation and removal of non-adherent cells. D) Untreated or inhibitor-treated cells were placed in the upper well of a Transwell plate.
Cells were incubated for 4 hr at 37°C and migration determined at a range of concentrations of SDF-1 by fluorescence intensity in the bottom well
was higher (p < 0.01** for both) in inhibitor-treated cells. fMSC were treated with either vehicle, 80 μM of blebbistatin or dynasore for 2 hours and the
media then replaced with either (E) osteogenic- or (F) adipogenic-induction media. After 3 weeks culture, differentiation was determined by Alizarin
Red (osteogenesis) or Oil Red O (adipogenesis) staining. Undifferentiated fMSC cultured in normal growth media are shown on the right.
Pelekanos et al. BMC Cell Biology 2014, 15:15 Page 11 of 15
http://www.biomedcentral.com/1471-2121/15/15lysosomes (Figure 2A-C) [38]. The kinetic profile of
CXCR4 trafficking in fMSC as supported by translocation
modelling indicates that CXCR4 endocytosis rate regulates
surface expression of CXCR4. Together this indicates a
state of accelerated internalization of CXCR4 in resting
fMSC (Figure 3), which when relieved by inhibition of
endocytosis led to an increase in CXCR4 surface expres-
sion and potentiated fMSC migration toward an SDF-1α
gradient in Transwell assays (Figure 6D).
Flow cytometry data indicate that there was up to 10-
fold increased CXCR4 expression at the cell surface after
blebbistatin treatment (Figure 3B and D). However this
was difficult to confirm conclusively with microscopy
due to the differences in sensitivity between the two tech-
niques and the low total expression of CXCR4 in fMSC,
or alternatively perhaps because inhibiting endocytosis isnot the main mechanism of the increase in surface
CXCR4. This 5-10-fold increase in surface CXCR4
expression, with a 2.6 fold increase in migration index,
is superior to what has been reported for genetic over-
expression of CXCR4. Recently Marquez-Curtis et al.
reported that non-transfected human fetal umbilical
cord blood-derived (UCB)-MSC had <2% CXCR4+ popu-
lation [9]. However, after transiently transfecting with a
CXCR4 expression construct, 40% of cells were CXCR4+,
resulting in a ~3-fold increased migration to SDF-1. Fur-
thermore, Marquez-Curtis et al. claim their transient
transfection method in fetal UCB-MSC produced superior
results to other expression methods in adult rat MSC,
which although increased CXCR4 expression to 54-95% of
cells, but showed a mere 2–3 fold increased migration to
SDF-1 [9,15,39].
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cytoskeletal morphology is not unexpected as mechanis-
tically they transiently disrupt cytoskeletal components
myosin IIA and dynamin [40]. Therefore, a small mol-
ecule with reversible effects, such as blebbistatin, is likely
to be more effective at enhancing migration rather than
over expression or knock down approaches to a single
chemokine receptor/ligand. However, this cytoskeletal
disruption also makes the cells less adherent and more
sensitive to handling.
Although we only used one adult MSC donor in this
study, the small number of cells expressing CXCR4 at
the plasma membrane was similar to what we found
with nine fetal MSC donors and as reported by others
for adult MSC [30]. Surface expression of CXCR4
reported in adult MSC has been variable, in the range of
2-25% of cells [41-43]. In keeping with this, there was a
disparity between the 4% of cells we found with surface
CXCR4 expression in first trimester bone marrow fMSC
compared to the Jones et al. figure of 23% in blood-
derived fMSC [18]. Indeed discrepancies on levels of
other fMSC markers in particular Oct4, between our
collaborating laboratories was the subject of a recent
review [44]. This difference in CXCR4 expression might
reflect inherent biological variation in MSC samples (donor
or organ sourced, age, sampling method) coupled with
differing methods of culture (serum batch) or different
antibodies used in analysis.
Our finding of nuclear localized CXCR4 in bone marrow
fMSC is consistent with recent findings in blood fMSC
[18]. The human CXCR4 contains a nuclear localization
motif [45] and nuclear CXCR4 translocation has been re-
ported to be a negative prognostic marker in several highly
proliferative cancers [46-49]. Furthermore, a number of
studies have found, similar to our study, that different
antibody clones against CXCR4 can show disparate sub-
cellular localization patterns, including some with nuclear
localization and others with cytoplasmic localization of
CXCR4 [50]. This could be due to the epitope recognised
by the antibody; for example the epitope of the CXCR4
ab2074 antibody, which we found to detect the nuclear
CXCR4, is the N-terminal 20 amino acids, 9 residues of
which differ between the CXCR4 mRNA splice variants 1
and 2 [51,52]. A number of molecular weight forms of
CXCR4 protein have been described by western blotting
of various cells and tissues, which have been determined
to be due to splice variants, dimeric receptors, and post-
translational modifications [32,53].
Fetal MSC express both CXCR4 and its ligand SDF-1 as
confirmed here. Reports of an inverse correlation between
CXCR4 and SDF-1 expression by MSC [54], is one possible
explanation for our finding. That is, endogenously pro-
duced SDF-1 binds surface CXCR4, induces internalization
of CXCR4, and potentially forms a suppressive autocrineloop down regulating CXCR4 expression. To investigate
this we showed that treatment with a neutralizing antibody
against SDF-1, resulted in only a small increase in surface
expression of CXCR4 (p < 0.01). Furthermore, prolonged
treatment or increased antibody concentration, which
would be expected to lessen autocrine suppression, did not
restore CXCR4 surface expression to a substantial level.
Thus while autocrine SDF-1 may trigger some ligand-
dependent CXCR4 internalization, this is not the principal
mechanism responsible for intracellular localization of
CXCR4 in fMSC. These data also support previous find-
ings in non-MSC cell lines [53].
The chemokine receptor and other migratory mecha-
nisms in MSC are not well understood, leading to
seemingly contradictory findings in the literature [55-61].
This may be due to different migratory assays detecting
different type of cellular movements. Similarly, we found
that blebbistatin and dynasore did not have any effect on
two dimensional migration in the scratch wound assay,
but did have a significant increase in the number of cells
that migrated in transwell assay in response to SDF-1. In
the transwell assay, cells migrate through a membrane in
response to a chemotactic ligand (e.g. SDF-1), mimicking
an in vivo injury paradigm. Different migratory effects
observed may also depend on the suite of chemokine
receptors and ligand isoforms expressed by MSC, and the
in vitro or in vivo environment [58]. Furthermore, a num-
ber of studies ignore the capacity of CXCR4 to cross talk
with other receptors directly or indirectly, especially
the heterodimerizing CXCR4-CXCR7 pair [41,62] or
have alternative ligands [57,63]. Nor do they take into
account that the ligands of CXCR4 and CXCR7 homo-
and heterodimeric complexes, SDF-1 and MIF, are
highly expressed by MSC [64]. Park et al. demonstrated
CXCR4-overexpressing MSC displayed enhanced migra-
tion to SDF-1, but more so to glioma-conditioned media,
which contains a multitude of migratory factors [65].
Conclusions
In conclusion, this study is the first to propose a reversible,
small molecule method for enhancing MSC migration.
Understanding the novel role of the cytoplasmic and nu-
clear localised CXCR4 described here may further augment
fetal MSC migration for translation therapeutic uses.
Additional files
Additional file 1: Pelekanos et al. Supplementary Text R1.
Additional file 2: Figure S1. Characterization of fetal Mesenchymal
Stem/Stromal Cells. A) Light microscopy (x10 magnification) of fetal MSC
showing an adherent, fibroblast like morphology. Fetal MSC display
osteogenic (B), adipogenic (C) and chondrogenic (D) differentiation capacity
after incubation with specific induction media and staining with Alizarin Red,
Oil red-O or Alcian Blue respectively (x4, x10 and x2 magnification respectively).
E) Flow cytometry for MSC positive markers: CD73, CD105, CD90, CD44,
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http://www.biomedcentral.com/1471-2121/15/15HLA-ABC, CD29, CD49b, CD49d. F) Flow cytometry for MSC negative
markers: CD11b, CD34, CD45, CD117, CD31, HLA-DR, CD14. Fluorophore
conjugates are indicated.
Additional file 3: Figure S2. Flow cytometry of CXCR4 expression by MSC
control cell lines. Three different anti-CXCR4 antibody clones were used 12G5,
ab2074 and 4417 as detailed in the methods, with fluorophore labelled
secondary antibodies used where necessary. A) Fetal MSC CXCR4 surface
expression (cell count vs fluorescence intensity) by flow cytometry shown as
histograms plots (same data as for Figure 3). B) After permeabilization, the
majority of cells show intracellular stores of CXCR4. Red histogram indicates
isotype control. Human adult bone marrow MSC also show low expression of
CXCR4 on the cell surface (C) but large intracellular store of this receptor (D).
E and F) All the anti-CXCR4 antibodies are able to detect >80% cells with
surface expression of CXCR4 on HeLa human cervical cancer cells. G) Both the
anti-CXCR4 antibodies 12G5 and ab2074 are able to detect >80% cells with
surface expression of CXCR4 on THP-1 human monocytic leukaemia cells. H)
Fetal MSC were detached with TrypLE trypsin replacement or 5 mM EDTA
and stained with CXCR4 (12G5) antibody to assess the effect of enzymatic
dissociation on the number of cells staining positive for surface CXCR4.
Additional file 4: Figure S3. Optimization of the fixation and
permeabilisation conditions for the anti-CXCR4 (ab2074) antibody in fMSC
or HeLa cells. (A and B) fMSC or HeLa cells were fixed and permeabilised as
follows (from left to right): methanol, 4% paraformaldehyde (PFA) + 0.3%
Triton and PFA + 0.1% Tween, and then stained with CXCR4 (ab2074) as
detailed in the methods section. The negative control was PFA + Triton
treated cells but the primary CXCR4 antibody omitted. C) HeLa cells with
the anti CXCR4 antibody clone ab2074 or 12G5, where the cells were fixed in
PFA to show surface staining or treated with PFA + Triton to show intracellular
staining. D and E) Fetal MSC and HeLa cells were transiently transfected with
Rab5-GFP or Rab11-GFP constructs to ensure the accuracy of the Rab antibody
staining. Note that Rab5-GFP shows classic punctate endosomal localization in
both fMSC and HeLa, whereas the Rab11 shows diffuse cytoplasmic
localization in fMSC and classical endosomal punctae in the HeLa cells,
similar to antibody staining in Figure 2.
Additional file 5: Figure S4. Two compartment modelling of CXCR4
trafficking. (A) Real time PCR for SDF-1: Expression of SDF-1 in fMSC (n = 4)
shows SDF-1 and CXCR4 transcripts relative to the housekeeping gene
GAPDH. B) Kinetics of CXCR4 exocytosis in fMSC after treatment with
endocytosis inhibitors: Cells were treated with 80 μM blebbistatin or
80 μM dynasore then fixed and stained with anti-CXCR4. Surface expression
was determined by flow cytometry and data fitted to a two-compartment
model of endocytosis (same data as Figure 1C). C) Fit of CXCR4 surface
expression data for naïve (kr = 0.04 min
−1, ke = 0.79 min
−1), blebbistatin-
(kr = 0.04 min
−1, ke = 0.078 min
−1, r2 = 0.89) and dynasore-treated cells
(kr = 0.03 min
−1, ke = 0.09 min
−1, r2 = 0.91) to the two compartment model.
Simulation was initiated with cytoplasm (endosomes) containing the entire
cellular CXCR4. Response of surface expression to changes in the endocytosis
rate (ke): kr was maintained at 0.04 min
−1 while ke was varied from 0.79 min
−1
to 0.02 min−1. D) Data that was used in the mathematical modelling of CXCR4
trafficking.
Additional file 6: Figure S5. Endocytosis inhibitors have a rapid but
transient effect on fMSC morphology. Light microscopy images show
morphology of fMSC rapidly changes from wide flattened fibroblast-like
state (far left panels, 0 min) to cells that become rounded in the centre
with long projections after vehicle (DMSO), blebbistatin and dynasore
treatment. Cell morphology returns to normal by 24 hr post treatment
and removal of the reagents (x10 magnification).
Additional file 7: Figure S6. Comparison of fMSC survival after
inhibitor treatment. A) The Picogreen assay showed that there was no
significant difference in the number of cells in control (serum free
media), vehicle (0.45% DMSO) conditions or with increasing dose of
blebbistatin for 1 hr. B) 7-AAD dye exclusion analysed by flow cytometry
showed no significant difference between control media (vehicle) and
blebbistatin treated fMSC after 1 hr incubation.Abbreviations
CXCR4: chemokine receptor C-X-C motif 4; F: fetal; MSC: mesenchymal stem
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